Notice of Interim Results 2014

Cathay International Holdings Limited

("Cathay" or the "Company")

Notice of Interim Results 2014

Hong Kong, 19 August 2014 - Cathay International Holdings Ltd. (LSE: CTI.L), an investment holding company and a leading investor and operator in the growing healthcare sector in the People's Republic of China ("PRC"), today announces that the Company will issue its Interim Results for the six months ended 30 June 2014 on Friday 29 August 2014.

-ENDS-

For further enquiries, please contact:

About Cathay

Cathay International Holdings Limited (LSE: CTI.L), focused on the People's Republic of China ("PRC"), is an investment holding company and a leading investor and operator in the growing healthcare sector in the People's Republic of China ("PRC"). The Group employs more than 2,000 people across the PRC, including over 30 specialist corporate and business development staff based at the holding company's offices in Hong Kong and Shenzhen.

Cathay aims to identify business opportunities with emphasis on high growth healthcare markets and build them into market sector leaders, with a clear exit strategy. Cathay has demonstrated a strong track record of identifying high-growth potential investment opportunities in this area including: Lansen Group, China's leading specialty pharmaceutical company focused on rheumatology and dermatology; Haizi Group, a company engaged in the manufacture, marketing and sale of inositol and DCP; and the Yangling group, a company engaged in the extract and trading of key active ingredients for healthcare products, including inositol. To complement its healthcare portfolio, Cathay has a research and product development business focused on bringing new products to the growing Chinese market.

Cathay also has a hotel investment. For more information please visit the Company's website: www.cathay-intl.com.hk.